Independent prognostic significance for tumor-associated inflammation was outlined in BRCA-associated TNBC [45], along with the interplay between BRCA1/2 defects and homologous recombination deficiency (HRD) scores, even in the presence of higher predicted neoantigen load, which was shown to dictate overall tumor immunogenicity [46]. The gene discussed is BRCA1; the disease is neoplasm.